evo真人视讯

Overseas Biopharmaceutical Ph.D. Delegation Visits Shenzhen-Hong Kong Cell Valley – Exploring CGT Frontiers and Cross-Border Innovation Cooperation

Date:11-13  Hits:  Belong to:News

图片.png

Recently, a delegation of 20 Ph.D. holders—high-level overseas biopharmaceutical talent—visited the Shenzhen-Hong Kong Cell Valley. The members come from various countries and regions including Europe, the United States, and Australia, and hold positions at multiple top global pharmaceutical companies and world-renowned universities, covering core R&D roles such as scientists, R&D directors, and postdoctoral researchers. Their research directions span frontier fields including AI drug development, synthetic biology, cell and gene therapy (CGT), tumor immunology, bioprocessing, and bioinformatics. Dr. Fu Yuchen, Director of the International Medical Service Center of the Cell Valley Group, warmly received the delegation.

图片.png

In the smart exhibition hall, Dr. Fu Yuchen introduced the Cell Valley Group's development trajectory and strategic layout, with a focus on the policy opportunities for the CGT industry in the Greater Bay Area, the trinity technology platform architecture of "viral vectors + cell preparation + exosomes," and the full-chain CDMO service system covering everything from sequence design and process development to quality testing and release validation.

图片.png

During the visit, the delegation members, drawing on their own research directions, engaged in exchanges with the Cell Valley team on professional topics including viral vector process scale-up, cell preparation processes and cost control, gene delivery efficiency and safety, exosome delivery, and regulatory filings. They also expressed interest in Cell Valley's progress on exosome INCI filing and FDA DMF applications. The two parties further discussed topics including the translation bottlenecks of CGT pipelines moving from the laboratory to the clinic, the application prospects of AI-assisted drug design, process optimization directions driven by synthetic biology, and cell and gene therapy strategies for neurodegenerative diseases. Dr. Fu Yuchen also shared Cell Valley's practical experience in international compliance registration, cross-border viral vector transportation, and regional industrial collaboration.

This visit built a pragmatic exchange platform for high-level overseas biopharmaceutical talent and the Greater Bay Area's CGT innovation platform, further enhancing mutual understanding between the two parties on technology pathways and industrial collaboration. Both parties unanimously stated that they will take this exchange as an opportunity to continuously deepen cooperation around specific technical project matching, joint R&D breakthroughs, and talent exchange and interaction, jointly exploring new pathways for cross-border industrial collaboration and promoting the efficient alignment of overseas innovation resources with the Bay Area's industrial capabilities.


About Us
Scan to follow our latest newsScan to follow our latest news
Contact Us
400-800-1266

Working hours: Monday to Friday, 9:00-18:00

Contact:Ms. Lai

Email:laijiaqi@rodael.com

Address:No. 1, Rongtian Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen, China (Hepure Biomedical Ecological Park)

Cell Valley Group is a leading CGT infrastructure platform in China. We capitalize on the strategic window opened by Decree No. 818 to bridge the gap between clinical research and commercialization.

We pioneer the "Hospital to Industry" (H2I) model. Basically, we act as the core partner for hospitals, providing a one-stop solution for new biomedical tech—covering process development, GMP manufacturing, QC, and commercial rollout. Our mission is to push China's CGT sector from pure R&D into a standardized, scalable industry.
 Copyright 粤ICP备2024168379号 互联网药品信息服务资格证书:(粤)-非经营性-2022-0426  Technical Support:YouDian Software